Hanmi Pharmaceutical is about to win the market for erectile dysfunction treatments. While "PalPal," the No. 1 item in the existing market, was leading, third-place Gugu chased second-place Chong Kun Dang's Cendom.

According to IQVIA, a pharmaceutical market research institute, on the 28th, the domestic erectile dysfunction treatment market in the first quarter was 27.7 billion won. It increased by 9% compared to 25.4 billion won in the first quarter of last year.

Most of the major products also saw their sales increase year-on-year. Hanmi Pharmaceutical's PalPal, which maintains its market lead, increased 2% from 5 billion won in the first quarter of last year to 5.1 billion won in the f